Stockscreener 앱 받기
13.39
9.93%
1.21
시간 외 거래:
13.90
0.51
+3.81%
전일 마감가:
$12.18
열려 있는:
$13.74
하루 거래량:
19,473
Relative Volume:
0.27
시가총액:
$347.53M
수익:
$26.00M
순이익/손실:
$-219.71M
주가수익비율:
-0.2689
EPS:
-49.8
순현금흐름:
$-51.37M
1주 성능:
+0.90%
1개월 성능:
+36.22%
6개월 성능:
-31.05%
1년 성능:
-21.28%
1일 변동 폭
$13.39
$13.81
1주일 범위
$11.80
$13.81
52주 변동 폭
$8.46
$26.50
Cartesian Therapeutics Inc Stock (RNAC) Company Profile
명칭
Cartesian Therapeutics Inc
전화
301-348-8698
주소
7495 NEW HORIZON WAY, FREDERICK
RNAC을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RNAC
Cartesian Therapeutics Inc
|
13.39 | 316.12M | 26.00M | -219.71M | -51.37M | -49.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
476.95 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.39 | 60.56B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.64 | 42.41B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
575.42 | 34.96B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
294.83 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Cartesian Therapeutics Inc Stock (RNAC) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-09 | 개시 | Wedbush | Outperform |
| 2024-12-19 | 개시 | BTIG Research | Buy |
| 2024-08-06 | 개시 | TD Cowen | Buy |
| 2024-07-02 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2024-06-04 | 개시 | Oppenheimer | Outperform |
| 2024-05-24 | 개시 | Mizuho | Buy |
| 2024-04-23 | 재확인 | H.C. Wainwright | Buy |
| 2024-04-23 | 개시 | Leerink Partners | Outperform |
| 2023-08-18 | 다운그레이드 | SVB Securities | Outperform → Market Perform |
| 2022-06-14 | 재확인 | Needham | Buy |
| 2022-06-06 | 개시 | SVB Leerink | Outperform |
| 2021-06-15 | 개시 | BTIG Research | Buy |
| 2021-01-26 | 업그레이드 | Mizuho | Neutral → Buy |
| 2020-10-01 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2020-10-01 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2020-06-12 | 다운그레이드 | Stifel | Buy → Hold |
| 2020-04-28 | 개시 | H.C. Wainwright | Buy |
| 2020-01-29 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-01-21 | 개시 | William Blair | Outperform |
| 2018-06-27 | 개시 | Janney | Buy |
| 2017-03-30 | 재확인 | UBS | Buy |
모두보기
Cartesian Therapeutics Inc 주식(RNAC)의 최신 뉴스
Cartesian Therapeutics Inc. Stock Analysis and ForecastFree Daily Trading Room Entry - Autocar Professional
Is Cartesian Therapeutics Inc. a good long term investmentStrongest growth potential - Autocar Professional
What drives Cartesian Therapeutics Inc. stock priceRapid growth trajectories - jammulinksnews.com
What analysts say about Cartesian Therapeutics Inc. stockFree Stock Market Forecast Reports - jammulinksnews.com
What makes Cartesian Therapeutics Inc. stock price move sharplyFree Stock Market Swing Trading Strategies - Newser
Multiple Myeloma Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis CASI Pharmaceuticals, Carsgen Therapeutics, Cartesian Therapeutics - MenaFN
Why Cartesian Therapeutics Inc. stock attracts strong analyst attentionCarefully Curated High Return Stocks - Newser
How Cartesian Therapeutics Inc. stock performs during market volatilityShort Squeeze Radar - Newser
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Receives $40.00 Average Price Target from Analysts - Defense World
What is Wedbush’s Estimate for RNAC Q2 Earnings? - Defense World
Cartesian Therapeutics Advances mRNA CAR T-cell Therapy for Myasthenia Gravis - TipRanks
Wedbush Initiates Coverage on Cartesian Therapeutics (NASDAQ:RNAC) - Defense World
CartesianAutoimmune Cell Therapy Excites, But Reality Bites (NASDAQ:RNAC) - Seeking Alpha
Wedbush initiates coverage on Cartesian Therapeutics stock with Outperform rating - Investing.com Canada
Cartesian stock up as Wedbush becomes bullish (RNAC:NASDAQ) - Seeking Alpha
Cartesian Therapeutics' 15min chart sees KDJ Golden Cross, bullish Marubozu formation. - AInvest
AbbVie Makes Big Autoimmune CAR-T Play With Capstan Acquisition - insights.citeline.com
What caused RNAC's earnings to miss forecasts in Q4 2023? - AInvest
Rhumbline Advisers Grows Stock Position in Cartesian Therapeutics, Inc. (NASDAQ:RNAC) - Defense World
We're Not Very Worried About Cartesian Therapeutics' (NASDAQ:RNAC) Cash Burn Rate - Yahoo Finance
Myasthenia Gravis Market to Expand Significantly by 2034, States DelveInsight Report | Sanofi, Cartesian Therapeutics, Takeda, UCB Biopharma, Hoffmann-La Roche, Janssen Research & Development, LLC - The Globe and Mail
IBM Introduces Industry-First Software to Unify Agentic Governance and Security - The Globe and Mail
Cartesian Therapeutics holds annual stockholders meeting By Investing.com - Investing.com South Africa
Cartesian Therapeutics holds annual stockholders meeting - Investing.com
Cartesian Therapeutics Holds Annual Stockholders Meeting - TipRanks
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Shares Acquired by Bank of America Corp DE - Defense World
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
Two Sigma Investments LP Reduces Holdings in Cartesian Therapeutics, Inc. (NASDAQ:RNAC) - Defense World
Equities Analysts Offer Predictions for RNAC FY2026 Earnings - Defense World
Nuveen Asset Management LLC Buys 47,889 Shares of Cartesian Therapeutics, Inc. (NASDAQ:RNAC) - Defense World
Cartesian Therapeutics Announces New Employment Inducement Grants - GlobeNewswire
Cartesian Therapeutics Announces New Employment Inducement Grants | RNAC Stock News - GuruFocus
Cartesian Therapeutics (RNAC) Issues Inducement Stock Options to New Employees | RNAC Stock News - GuruFocus
Cartesian Therapeutics Awards 26,350 Stock Options to Key New Hires in Autoimmune Disease Research - Stock Titan
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Shares Acquired by MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. - Defense World
H.C. Wainwright maintains buy rating on Cartesian Therapeutics stock By Investing.com - Investing.com Nigeria
Cartesian Therapeutics Inc (RNAC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Cartesian Therapeutics Inc 주식 (RNAC) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| English Emily | Chief Operations Officer |
Apr 15 '25 |
Option Exercise |
3.30 |
7,500 |
24,750 |
47,726 |
| SPRINGER TIMOTHY A | Director |
Apr 10 '25 |
Buy |
10.47 |
48,595 |
508,751 |
620,175 |
| SPRINGER TIMOTHY A | Director |
Apr 09 '25 |
Buy |
9.43 |
41,782 |
393,947 |
571,580 |
| SPRINGER TIMOTHY A | Director |
Apr 11 '25 |
Buy |
10.77 |
36,338 |
391,455 |
656,513 |
| SPRINGER TIMOTHY A | Director |
Apr 10 '25 |
Buy |
10.47 |
8,575 |
89,773 |
8,637,273 |
| SPRINGER TIMOTHY A | Director |
Apr 09 '25 |
Buy |
9.43 |
7,373 |
69,517 |
8,628,698 |
| SPRINGER TIMOTHY A | Director |
Apr 11 '25 |
Buy |
10.77 |
6,412 |
69,074 |
8,643,685 |
| SPRINGER TIMOTHY A | Director |
Mar 20 '25 |
Buy |
15.59 |
54,889 |
855,593 |
8,621,325 |
| SPRINGER TIMOTHY A | Director |
Mar 19 '25 |
Buy |
14.97 |
20,234 |
302,962 |
8,566,436 |
| SPRINGER TIMOTHY A | Director |
Mar 18 '25 |
Buy |
14.42 |
14,740 |
212,599 |
8,546,202 |
4.91%
0.25%
자본화:
|
볼륨(24시간):